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INTRODUCTION 
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HIV infection is a global pandemic, with cases of AIDS reported in 
nearly every country in the world. Infection with the human 
immunodeficiency virus-type-1 (HIV-1) can have a significant impact on 
the central nervous system (CNS) as well as on the immune system. 
Michael Gottlieb(1981) diagnosed with Pneumocystis carinii  pneumonia 
in a gay man and some rare cases of Kaposi’s sarcoma were diagnosed 
during the same period. All these patients were strangely immuno 
deficient—their immune systems could not fight off even simple 
infections. Other opportunistic infections accompanied these diagnoses. 
The initial diagnosis was given the incriminating acronym GRID, 
Gay Related Immunodeficiency Disease. Since male homosexuals and 
intravenous drug users were frequent blood donors, for both altruistic and 
financial reasons, the blood supply was quickly tainted. Suddenly 
hemophiliacs living outside the usual risk areas, who needed Factor VIII, 
which was extracted from the whole blood of thousands of donors, came 
down with the same symptoms. During 1982  AIDS  was diagnosed 
among hemophiliacs and injection drug users (IDUs). Later the first case 
of heterosexual transmission was identified in USA.(centers for disease  
control and prevention, 1983). 
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The first studies performed by the CDC in 1981 traced the sexual 
contacts of a small group of 40 patients suffering from KS, PCP, and/or 
other opportunistic infections. All cases could be traced to the single 
index case, called Patient Zero, a French Canadian flight  attendant  
Gaetan  Dugas. Although Dugas was not the first person to show 
symptoms of HIV infection, he was the center of this particular cohort of 
diseased individuals. The earliest fully documented case of HIV dates 
back to 1959. A Congolese man's blood sample from a medical study was 
preserved, found, and then analyzed in 1998. It was verified that he had 
been HIV+. Other suspected, but unverified because of the lack of either  
blood or tissue samples, cases date back as early as 1934. 
Since the identification of HIV in 1981 ,neurologists described 
several HIV-related central nervous system (CNS) syndromes within the 
first several years of the epidemic. Mental health professionals from 
nursing, social work, psychology, and psychiatry followed the plight of 
patients of the epidemic and helped to mobilize interest and galvanize a 
response. Initially, much of the work focused on grief and loss issues, as 
well as supportive psychotherapy, but quickly broadened to recognize a 
number of specific psychiatric conditions, including acquired immune 
deficiency syndrome (AIDS) dementia, Cognitive Impairment, the 
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associated AIDS mania, increased rates of major depression, and 
psychiatric consequences of CNS injuries. 
Neuropsychiatric disorders in HIV can be either primary or 
secondary. Primary complications are those that can be attributed directly 
to the infection of the   central nervous system by the virus, or to imuno 
pathological events precipitated by HIV infection. Primary HIV-related 
brain disorders include HIV-related dementia and minor cognitive   
disorder. 
  Immune suppression can lead to a variety of secondary 
complications affecting the brain, including opportunistic infections (e.g. 
cerebral toxoplasmosis and progressive multifocal leucoencephalopathy) 
and tumours (e.g. cerebral lymphoma). Secondary complications in the 
form of acute and subacute syndromes (e.g. delirium) often occur as a 
result of cerebrovascular complications and toxic states induced by 
various therapeutic agents. 
Five   percentage of newly diagnosed AIDS cases and 60% in late 
AIDS have been found to be impaired, (Tozzi et al, 2005, Cysique et al 
,2004, Yepthomi et al ,2006). Neuropsycholgical impairment caused by 
HIV was found in the areas of attention and concentration, abstraction, 
learning, memory, psychomotor and cognitive processing speed in several 
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studies.(Bornstein et al., 1993; Heaton et al., 1995;  McArthur and Seines, 
1997, Glen et al, 2005).  
Age, CD4 count, Education, Employment are the some of the 
factors predicting the development of cognitive impairment, proposed by 
few literatures.  
Pharmacologic treatment strategies for cognitive disorders can be 
divided into four types: 1) antiretroviral therapies, 2) therapies aimed at 
immunological measures or inflammatory mediators, 3) therapies aimed 
at bolstering the response of the brain to the onslaught of the infection 
(e.g., neurotransmitter manipulation), and 4) nutritional therapies. Most 
controlled studies have investigated the efficacy of antiretroviral 
therapies, and while these studies have advanced our knowledge about 
interventions for cognitive disorders, several key factors required to be 
considered. First is the fact that most published studies to date report on 
the treatment strategy of administering a single antiretroviral agent. Their 
findings are therefore difficult to interpret in light of the multi drug 
regimens that are now the standard of care in developed countries. 
Second, the reports vary widely with regard to the study population, since 
some studies enrolled subjects on the basis of established criteria for 
HIV-associated dementia or minor cognitive motor disorder but other 
studies enrolled cognitively impaired subjects without Specifying 
12
 
whether they also met criteria for a clinical disorder. Third, the range of 
HIV clinical severity also varied widely in study subjects. Whether 
antiretroviral agents penetrate the blood-brain barrier sufficiently to 
adequately suppress viral replication is a key issue that requires further 
study. 
Scope of this study: 
This study focused on the primary neuropsychiatric disorders of 
HIV and cognitive impairment in particular. There is some evidence to 
suggest that CD4 count was an important predictor of the development of 
immune deficiency and subsequent cognitive impairment. .This study 
aims to corroborate on the prevalence of cognitive impairment in HIV 
patients and to know whether CD4 count are correlated with the 
impairment and the effect of antiretroviral therapy in the cognitive 
impairment 
Plan of the study: 
 The present study has been planned as follows     
 Review of Literature 
 Methodology 
 Results and Interpretation 
 Discussion 
 Conclusion 
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REVIEW OF LITERATURE 
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HIV was originally recognized through a series of case descriptions 
involving young homosexual men with Pneumocystis carinii pneumonia in 
the early 1980s in Los Angeles. Subsequently, it became clear that these 
patients had severe immune system compromise and were vulnerable to 
infections that had been seen in other immuno compromised individuals. 
Recent estimates indicate that up to 40 million people are infected 
worldwide, and another 20 million have died from HIV disease. 
Currently, 750,000 babies are born each year with HIV infection. Some 
estimate that 16,000 new infections occur each day, and that one 
individual is infected with HIV approximately every 10 seconds. 
(UNAIDS ,2008  ). 
In 2006 UNAIDS estimated that there were 5.6 million people 
living with HIV in India, which indicated that there were more people 
with HIV in India than in any other country in the world( UNAIDS 
2007).  However, NACO disputed this estimate, and claimed that the 
actual figure was lower. (NACO,  2006). In 2007, following the first 
survey of HIV among the general population, UNAIDS and NACO 
agreed on a new estimate – between 2 million and 3.6 million people 
living with HIV. (NACO,UNAIDS,WHO-2007).The figure was 
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confirmed to be 2.4 million in 2008 (NACO,2007).This puts India behind 
South Africa and Nigeria in numbers living with HIV.  
In terms of AIDS cases, the most recent estimate comes from 
August 2006, at which stage the total number of AIDS cases reported to 
NACO was  1, 24, 995. Of this number, 29% were women, and 36% were 
under the age of 30 (NACO, 2007). These figures are not accurate 
reflections of the actual situation, as large numbers of AIDS cases go 
unreported.( NACO, 2007).Overall, around 0.3% of India’s population is 
living with HIV While this may seem a low rate, India’s population is 
vast, so the actual number of people living with HIV is remarkably high. 
There are so many people living in India that a mere 0.1% increase in 
HIV prevalence would increase the estimated number of people living 
with HIV by over half a million. (Kumar et al, 2006). 
Epidemiological studies in India show that HIV-C is the most 
prevalent virus and men are roughly four times more infected than 
women and that rural inroads are evident (Panda, 2006).According to 
NACO(2007) , Southern states like Tamilnadu, Andhra Pradesh, 
Karnataka were harboring more than half of the HIV patients. In Andhra, 
the HIV prevalence at antenatal clinics was 1.26% in 2006 - higher than 
in any other state - while the general population prevalence was 0.97% in 
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2005-2006. The vast majority of infections in Andhra Pradesh are 
believed to result from sexual transmission. HIV prevalence at STD 
clinics was 24.4% in 2006. In Karnataka the average HIV prevalence at 
antenatal clinics has exceeded 1% . Among the general population, 0.69% 
was found to be infected in 2005-2006. The average HIV prevalence 
among female sex workers in Karnataka was 8.64% in 2006, and 19.20% 
of men who have sex with men were found to be infected. In 
Maharashtra, 2005-2006 survey found an infection rate of 0.62% in the 
general population of Maharashtra. This state is home to around one in 
five of all people living with HIV in India. Some small North eastern 
states like Manipur, Mizoram contributed significantly in the 
development of HIV in IV drug abusers. The 2005-2006 survey found 
that 1.13% of the general population of Manipur was infected - the 
highest of all states surveyed(NACO,2007). 
Tamil Nadu 
When surveillance systems in the southern Indian state of Tamil 
Nadu, home to some 62 million people, showed that HIV infection rates 
among pregnant women were rising - tripling to 1.25% between 1995 and 
1997 .Tamil Nadu State AIDS Control Society (TANSACS) had been set 
up in 1994, through this organization all HIV related activities were 
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carried out.The HIV prevalence at antenatal clinics in Tamil Nadu was 
0.25% in 2006, though several districts still have much higher rates. The 
general population survey of 2005-2006 found a rate of 0.34% across the 
state. Prevalence among injecting drug users was 24.20% in 2006 - the 
highest of all states and union territories(NACO,2007). 
In Madurai, the annual report of ART centre revealed that 2274 
HIV cases were registered during 2005, of which 1568 were males and 
706 were females. The ART centre, Madurai was started in 2004, since 
it’s inception about 10,000 cases were registered till September 
2008.Among them about 4,000 patients received Anti retroviral Therapy.  
  HIV is a single-stranded ribonucleic acid (RNA) virus that 
selectively infects immune cells, particularly T lymphocytes and 
macrophages. RNA viruses use several strategies to infect cells and 
reproduce themselves. HIV is one member of a class of RNA viruses 
called retroviruses, all of which carry the enzyme reverse transcriptase 
(RNA-dependent deoxyribonucleic acid [DNA] polymerase) in the viral 
particle and depend on this enzyme for successful infection. Reverse 
transcriptase synthesizes viral DNA from the viral RNA strand. This 
DNA is then transported into the nucleus of the cell and directs the 
production of more viral RNA using the cell's synthetic machinery. This 
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DNA also may become inserted into the cellular DNA (where it is 
referred to as a provirus) and lie dormant, only to be activated at a much 
later time. 
HIV binds to specific recognition proteins found on the surface of 
certain cells of the immune system. Once bound, the virus is taken into 
the cell. At the same time, the outer coating of the viral particle is 
removed. The enzyme reverse transcriptase carried within the viral 
particle then begins the process of transcribing the viral RNA into DNA. 
This DNA moves to the nucleus of the cell where it directs the cell 
machinery to produce large quantities of viral messenger RNA (mRNA). 
The viral RNA then uses the cell's own machinery to produce the proteins 
required to make viral particles and other viral proteins. The viral 
particles are assembled around viral RNA, and the mature virions bud 
outward from the cell's surface. Finally, viral particles are cleaved from 
the cell surface and released into the host to infect other immune cells. 
(Adamson et al,1996; Johnson et al,1996; Seilhan et al,1997; Thompson 
et al,2001). 
The mechanism of HIV-associated cognitive–motor disorder is not 
fully understood. Although the productive HIV infection of the CNS is 
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probably essential, most investigators conclude that indirect mechanisms 
play a role. (Johnson et al, 1996;  Adamson et al, 1996). 
Products released by activated macrophages are prime candidates 
for neurotoxic mechanisms. The known neurotoxicity of tumor necrosis 
factor-_ (TNF_) and other studies demonstrating its expression in 
association with HIV encephalitis have suggested that this cytokine 
represents a critical factor in the pathophysiology of neurological 
dysfunction in HIV. (Wesselingh et al 1993; Seilhean   et al, 
1997;Thompson et al ,2001).  
Susan et al (2002) proposed the following mechanisms. (1)The 
predominant cognitive-impairing component of HIV-1 is its viral coat 
glycoproteins, (2) gp120 impairs memory by overstimulating pathways 
that normally sustain memory, (3) the cognitive effect of gp120 is 
mediated by its protein core, and (4) gp120 likely impairs memory by 
affecting the cholinergic/VIPergic system. 
Acquired Immunodeficiency Syndrome (AIDS) is a clinical 
syndrome resulting from the collapse of cell mediated immunity 
secondary to infection with the Human Immunodeficiency Virus-Type 1 
(HIV-1). The most common gross anatomical changes associated with 
AIDS include brain atrophy with sulcul widening and ventricular 
enlargement. Human immunodeficiency virus (HIV) appears to have a 
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predilection for subcortical structures, especially the frontal-subcortical 
systems (e.g., the basal ganglia).(Ketzler S et al ,1990;,Kuru K  et 
al,1990;Everall I et al,1991;Wiley C et al,1991).  Damage to these 
structures can cause specific motor and cognitive abnormalities, 
including poor fine-motor precision, memory deficits, and difficulties 
performing complex cognitive tasks.(Villa G et al,1993;Heaton R et 
al,1995).Damage to these systems can also cause significant neuro 
psychiatric syndromes, including depression, obsessive-compulsive 
disorder, mania, and apathy.(Hymas et al,1991;Cummings et 
al,1993).Another study  revealed high rates of depression (60%), 
dysthymic disorder (25%), and anxiety disorders (25%) among persons 
seeking HIV related mental health services in the public sector (Lyketsos 
et al,1996). That study  found high rates of comorbid substance use 
disorders, with nearly 50% of all patients  having a diagnosis of alcohol 
or drug dependence. Another clinical study in Madurai indicated that 
about 34% of HIV patients had depression. (Venkobao Rao, 1993) 
  One aspect of sub cortical neurological disease is the presence of 
motor and cognitive retardation including deficits in mental speed, 
spontaneity of action, spontaneity of speech for comment or question, 
initiative, and enthusiasm( Mapou et al,1993;Perkins et al ,1995). 
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  Histopathological analyses reveal white matter abnormalities, 
multinucleated giant cells of macrophage origin, microglial nodules, and 
diffuse reactive astrocytosis to be present in 70 to 90% of the brains of 
patients with AIDS who come to autopsy (Wiley 1994; Hardy et al 1999). 
HIV induced minor cognitive-motor disorder or mild 
neurocognitive disorder is a less severe   neurocognitive disorder 
emergent in earlier HIV infection .The symptoms of minor cognitive-
motor disorder are often overlooked, as they may be very subtle, but they 
are essentially mild manifestations of the same symptoms seen in HIV-
associated dementia: cognitive and motor slowing. Often, the disorder is 
discovered as a result of a singular minor complaint by a patient, such as 
taking longer to read a novel; dysfunction when performing fine motor 
tasks. The disorder is confirmed when mild impairments are present in at 
least two of the following domains: verbal/language, attention, memory 
(recall or new learning) abstraction, and motor skills. 
Definitional Criteria for HIV-Associated Minor Cognitive Motor 
Disorder is as follows (American Academy of Neurology, 1991). 
Probable Diagnosis (must meet all four criteria) 
1. Acquired cognitive/motor/behavioral abnormalities, verified by both a 
reliable history and by neuropsychological tests. 
2. Mild impairment of work or activities of daily living. 
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3. Does not meet criteria for HIV dementia or HIV myelopathy. 
4. No other etiology present. 
Prevalence data for minor cognitive-motor disorder are variable, 
often suggesting up to 60 percent prevalence by late-stage AIDS. 
Prevalence in earlier stages is not well defined, but the disorder has been 
anecdotally reported preceding a diagnosis of AIDS by 11 years. Subtle 
neuropsychological impairment may be found in 22%–30% of otherwise 
asymptomatic patients with HIV infection (Whilkie et al, 1990; White et  
al ,1995) 
Early in the AIDS epidemic, some patients presented with rapidly 
progressing neuro cognitive disturbances, leading to an intensive search 
for etiology. Several CNS opportunistic conditions were identified, 
including cytomegalovirus (CMV) encephalitis, progressive multifocal 
leukoencephalopathy (PML), cerebral toxoplasmosis, cryptococcal 
meningitis, and CNS lymphoma. However, a subset of patients remained 
for which no identifiable pathogen could be found, and it was deduced 
that HIV itself was the causative factor behind the dementia. Autopsy 
studies of demented AIDS patients revealed characteristic white matter 
changes and demyelinization, microglial nodules, multinucleated giant 
cells, and perivascular infiltrates but a marked absence of HIV within 
neurons. This has led to the current theories of neuronal loss through 
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action of macrophages and microglial cells, through activation of 
cytokines and chemokines that trigger abnormal neuronal pruning, or 
through both. It appears that basal ganglia and nigrostriatal structures are 
affected early in the dementia process, with diffuse neuronal losses 
following. Typical late findings show an approximate 40 percent 
reduction in frontal and temporal neurons. (Ketzler et al  ,1990). 
Mild cognitive impairment refers to the transitional period between 
normal cognition and dementia, but is not an extension of normal ageing. 
Subjects with mild cognitive impairment have subtle but measurable 
cognitive impairment that is not severe enough to interfere with 
independent living.  
Prevalence data for minor cognitive-motor disorder are variable, 
often suggesting up to 60 percent prevalence by late-stage AIDS.  
Whether minor cognitive-motor disorder predisposes to HIV-associated 
dementia is also of some debate. It appears that some patients may 
continue to have minor problems, whereas another group progresses to 
frank dementia. (Glen Treisman et al, 2005). 
Neuro ICONA (Italian Cohort Naïve Antiretroviral) study done in 
2002 over 395 HIV Positive patients naïve to HAART with no severe 
psychiatric disorders using the following tests - Timed gait-motor speed, 
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Digit symbol test-selective attention, WHO/ULCA Auditory verbal 
learning test-verbal memory, Color Trails 2 –sustained attention,cognitive 
flexibility revealed that the prevalence of cognitive impairment was 
17.9percentage.(Starace et al, 2002) 
Mccutchan et al (2007) studied  286 patients by using Trail making 
A , B and Digit symbol Test found that over one quarter(27%) of 
participants exhibited impairment at their initial neuropsychological 
assessment, a rate twice that expected in a normal population. 
Rodriguez et al  s(2007)  data indicate that prevalence of 
neuropsychological impairment in stage A(asymptomatic) was 33%., 
41.2% in stage B (low symptomatology patient )  and of 70.7% in stage C 
(AIDS patients).The pattern of neuropsychological impairment  was 
consistent with fronto-subcortical type alterations. 
Another study done on Neurocognitive impairment and survival in 
a cohort of HIV-infected patients (Tozzi et al, 2005) revealed that among 
the 412 enrolled patients, 224 (54.4%) were neurocognitively impaired 
and 188 (45.6%) were neurocognitively unimpaired. Patients were 
administered measures of neurocognitive function (a battery of 17 
neuropsychological tests), clinical and neurological evaluation, laboratory 
testing, and brain imaging studies. They also suggest that HIV-associated 
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neurocognitive impairment (NCI) was recognized as an independent risk 
factor for death. 
Kevin Robertson et al study (2007) on pattern of 
neuropsychological impairmernt among HIV patients in Uganda 
demonstrated a relative decline in measures of verbal learning and 
memory, speed of processing, attention and executive function compared 
to HIV negative controls. This is a similar pattern to what has been found 
in the  USA, Europe and  Australian settings ,and would suggest that  the 
pattern of neuropsychological loss will be the  same with clade A and D 
HIV infection, (Miller et al ,1990),(Heaton et al 1995) In turn, this would 
suggest  that HIV clade A and D have the same underlying pattern of 
neuropathology. There is no significant difference in the fine and gross 
motor tests between HIV positive and negative groups. 
A Prospective case control study by Odiase et al (2007) with a  
total of 288 randomly selected subjects, comprising 96 HIV-positive 
symptomatic patients, 96 HIV-positive asymptomatic patients and 96 
HIV-negative controls. The Recognition Memory Test and Choice 
Reaction Time tasks, components of the computer-assisted 
neuropsychological tests battery- the Iron Psychology 'FePsy' were used 
for cognitive assessments indicated that HIV positive patients had 
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psychomotor slowing , impaired attention  and significant memory 
impairment. 
Wig et al(2004) studied 70 HIV patients and showed that 42% of 
subjects had HIV associated Mild Neurocognitive disorder. 1.02% had 
HIV associated Dementia and 1.02% had HIV associated Delirium .They 
also found that there was no significant association on multivariate 
stepwise regression analysis between cognitive functions and age, sex, 
and duration of disease, BMI, hemoglobin level except CD4 counts. 
Yepthomi et al’s (2006) data collected in Chennai-based study with a 
sample of 30 treatment-naïve HIV-positive individuals with a median 
CD4 cell count of 97, and 30 age and education matched healthy controls 
obtained from the same region of India revealed significant differences on 
most cognitive tests, with lower performances obtained by the HIV-
positive individuals. These results suggest that cognitive difficulties are 
present among individuals with the clade C virus in India, with as many 
as 56% of the patients with advanced HIV meeting the criterion for 
impairment in two cognitive domains. 
Gupta et al (2007) using Standardized neuropsychological tests   in 
a sample of 119 adults infected with clade C HIV-1 who were not on 
antiretroviral medications. Neuropsychological test performance was 
compared with gender-, age-, and education-matched normative data 
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derived from a sample of 540 healthy volunteers and a matched cohort of 
126 healthy, HIV-1-seronegative individuals. Among the seropositive 
subjects, 60.5% had mild to moderate cognitive deficits characterized by 
deficits in the domains of fluency, working memory, and learning and 
memory. None of the subjects had severe cognitive deficits. 
Venkoboa Rao’s study (1993) in Madurai,  with 67 HIV infected 
patients revealed that abnormality in visuo-motor function was detected 
in 68% of subjects. On the memory scale 54% were found to have verbal 
impairment, or non-verbal impairment or both.  
 
Predictors of Cognitive  Impairment: 
Age, CD4 count, Education, Employment are the some of the  
predicting factors in  the development of cognitive impairment ,proposed 
by few literatures . 
AGE: 
Older HIV individuals are 2 to 4 times more susceptible for 
development of cognitive impairment. According to Michael 
Garter(2004) 88% of HIV-positive patients aged under 40 had normal or 
equivocal cognitive function, only 56% of HIV-positive individuals over 
50 met this criteria. 
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Von Gorp et al (1994) did a cross-sectional observational study 
recruited 67 HIV-positive patients aged over 50, and 52 HIV-positive 
patients aged under 35. Both groups of patients underwent 
neuropsychological assessment and had CD4 cell counts and their plasma 
and CSF viral loads measured. HIV treatment histories were also 
obtained. They found an increased risk of cognitive impairment in HIV-
positive individuals aged over 50. Dementia was present in 22% of HIV-
positive patients over 50 at study baseline and 9% of HIV-positive 
individuals under 50 at the same study point. 
Valcour et al (2004) indicated that despite having lower HIV viral 
loads in plasma and cerebrospinal fluid, HIV-positive patients aged 50 
and above had a higher burden of neuropsychological impairment. 
Current estimates suggest that 10% of adults with AIDS are over 
50 years old and about 3% are over 60 years old.(Shipp et al, 1991;CDC 
1994, 1996; Chen et al., 1998 ).  Becker et al (1997)  found that test  
Performance declined with age. 
Sacktor et al (2007) done a study   in One hundred thirty-three 
older (age >or= 50 years) HIV+ individuals and 121 younger (age 20 to 
39 years). The older HIV positive.( total) cohort had greater impairment 
in tests of verbal memory, visual memory, verbal fluency, and 
psychomotor speed compared to the  Young HIV positive(total) cohort. 
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After adjusting for differences in education, older HIV  positive patients 
with dementia (n = 31) had a greater deficit in the Trail Making test Part 
B (P = 0.02) compared to younger HIV positive  patients with dementia 
(n = 15). Age was associated with lower performance in tests of memory, 
executive functioning, and motor performance in older HIV+ individuals 
with and without cognitive impairment (total cohort), compared to 
younger HIV+ individuals. 
Several theoretical models can be advanced that provide a rationale 
for expecting that age and HIV infection would interact. First, from the 
perspective of a brain or cognitive reserve capacity model (Satz, 1993), 
aging and HIV infection are considered as co-risk factors that reduce 
cognitive reserve capacity. The greater the reduction in reserve, the more 
likely that an impairment threshold will be crossed producing an 
observable neurocognitive deficit. Second, at a more specific conceptual 
level, perhaps aging and HIV infection have a common or significantly 
overlapping neuropathological locus therefore impairing the same 
neurocognitive processes. For instance, Hinkin et al. (1990) reported that 
the level and pattern of performance on neuropsychological testing was 
similar in a sample of young adults diagnosed with AIDS (mean age = 38 
years) and a group of older neurologically normal HIV seronegative 
adults (mean age = 70 years). The similar performance, despite an age 
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difference greater than 30 years, was attributed to a common mechanism, 
disruption of subcortical-frontal white matter connections. Similarly, 
behavioral slowing, a fundamental symptom of both aging and HIV 
infection, has been ascribed to basal ganglia dysfunction in both older 
(Bashore, 1993) and HIV-infected (Martin, 1994) adults. A third possible 
mechanism is that of a general slowing of cognitive operations. In other 
words, the uniform slowing of all cognitive operations produce the 
performance deficits observed in specific tasks. There is evidence for 
general slowing with age (Cerella, 1985; Salthouse, 1985) 
EDUCATION   
      Starace et al ’s(2002) Neuro ICONA study revealed that Global 
NeuroPsychological impairment was significantly more frequent 
(25.5%)in subjects with lower educational level(i.e. <8years of education) 
than >8years of educated subjects(9.7%).Ryan et al(2005) also gave a 
similar results in their study done with 200 subjects.  
UNEMPLOYEMENT: 
  Starace et al (2002) suggest that the impairment was more (28.2%) 
in unemployed than in employed subjects (10.3%).Similarly the 
impairment also lead to unemployment. Tozzi et al, 2004 with seventy 
subjects revealed that the health –related quality of life scores including 
social, occupational functioning was low in cognitively impaired patients. 
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CD4 COUNT 
The CD4 count can be used to track the progress of the infection 
and the status of the immune system. The average person has 
approximately 1,000 CD4 lymphocytes per mm3 (or µL) of blood. Before 
the development of effective treatment for HIV, the average patient's 
CD4 cell count dropped approximately 100 CD4 cells per mm3 (or µL) 
per year, and, thus, over a 10-year course was completely decimated. The 
immune system becomes quite compromised as the CD4 cell count drops 
below 200 per µL, and “cellular” immunity diminishes and is finally lost. 
As shown in the following   diagram, untreated patients with HIV 
infection have a brief severe decline in CD4 count immediately after 
infection. As the immune response to HIV begins the CD4 count returns 
to normal levels but then begins a slow decline. The CD4 count decreases 
by approximately 100 cells per year of infection in the average untreated 
patient. Over time, the effectiveness of immune function declines, and the 
patient may develop the conditions shown in the Figure. In the years 
before the development of effective treatment, this graph served as a kind 
of grim road map that ended inevitably in the death of the patient. (John  
Bartlett, 2005). 
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Gupta et al(2007) conducted a study  to assess cognitive 
functioning in a sample of 119 adults infected with clade C HIV-1 who 
were not on antiretroviral medications their performance was compared 
with gender-, age-, and education-matched normative data derived from a 
sample of 540 healthy volunteers and a matched cohort of 126 healthy, 
HIV-1-seronegative individuals. Among the seropositive subjects, 60.5% 
had mild to moderate cognitive deficits characterized by deficits in the 
domains of fluency, working memory, and learning and memory.. 
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Although the most immuno suppressed group (CD4 count < 200 
cells/mm3   or viral load > 1,000,001 copies) was small, their rate of 
impairment in visual working memory was greater when compared to 
groups with better immune function. 
Konov  (2007) supported the above findings with the following 
association between  CD4 count  cut-offs and the percentage of cognitive 
impaired subjects. 
 
CD 4 Count Percentages 
</=200 vs. >200 73.1 vs. 52.6 
</=250 vs. >250 66.7 vs. 53.3 
</=300 vs. >300 63.9 vs. 56.5 
</=350 vs. >350 57.1 vs. 62.5 
 
Wig et al (2004)   found that there was a significant negative 
correlation between CD4 count and time taken on Trail making part A, B 
and significant positive correlation between CD4 count and scores of 
block design and digit symbol (both imply poor performance with lower 
CD4 (<200cells) cell count. 
McCutchan et al (2007) documented improved performance on 
neuropsychological tests after  initiating HAART  .They also indicated 
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that this improvement  was marginally associated with the continued or 
improving control of plasma HIV-RNA levels, but not with concurrent 
levels of immune recovery (CD4 lymphocyte counts). 
Odease et al ‘s  (2007) data  collected from the following study 
with  a total of 288 randomly selected subjects, comprising 96 HIV-
positive symptomatic patients, 96 HIV-positive asymptomatic patients 
and 96 HIV-negative controls. The Recognition Memory Test and Choice 
Reaction Time tasks, components of the computer-assisted 
neuropsychological tests battery- the Iron Psychology 'FePsy' were used 
for cognitive assessments. The results  supported   McCutchan’s(2007) 
finding and stated that impaired ability for sustained attention was  
present irrespective of the CD4+ level relative to controls.But  HIV-
positive subjects with CD4+ counts < 200/microl and between 200 and 
499/microl had significant memory impairment (p < 0.001 and p < 0.001 
respectively) but there was no significant impairment among those with 
count > or = 500/microl. 
Salawu et al (2008) studied with a selected population of 60 
heterosexual asymptomatic treatment-naive HIV-positive subjects, They 
administered the Community Screening Instrument for Dementia (CSI-D) 
to assess language, memory, registration, attention and calculation, recall, 
praxis and orientation. HIV positives differed from individually matched 
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control subjects in certain measures of language expression, registration, 
attention and calculation, orientation to time, motor response and total 
CSI-D scores. The CD4 cell count of the HIV-seropositive subjects had 
no significant correlation with the cognitive test scores. 
AIDS dementia complex: 
AIDS dementia complex (ADC; also known as HIV dementia, HIV 
encephalopathy and HIV-associated dementia) is a common neurological 
disorder associated with HIV infection and AIDS. It is a metabolic 
encephalopathy induced by HIV infection and fueled by immune 
activation of brain macrophages and microglia.(Gray et al,2001).These 
cells are actively infected with HIV and secrete neurotoxins of both host 
and viral origin. The essential features of ADC are disabling cognitive 
impairment accompanied by motor dysfunction, speech problems and 
behavioral change.  
ADC stage characteristics: 
Stage 0 (Normal) Normal Mental and Motor Function 
Stage 0.5 (Subclinical) Minimal symptoms of cognitive or motor 
dysfunction characteristic of ADC, or mild signs (snout response, slowed 
extremity movements), but without impairment of work or capacity to 
perform activities of daily living (ADL). Gait and strength are normal. 
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¾ Stage 1 (Mild) Evidence of functional intellectual or motor 
impairment characteristic of ADC, but able to perform all but the 
more demanding aspects of work or ADL. Can walk without 
assistance. 
¾ Stage 2 (Moderate) Cannot work or maintain the more demanding 
aspects of daily life, but able to perform basic activities of self care. 
Ambulatory, but may require a single prop. 
¾ Stage 3 (Severe) Major intellectual incapacity - cannot follow news 
or personal events, cannot sustain complex conversation, 
considerable slowing of all output. And/or motor disability - cannot 
walk unassisted, requiring walker or personal support, usually with 
slowing and clumsiness of arms as well. 
¾ Stage 4 (End Stage) Nearly vegetative. Intellectual and social 
comprehension and responses are at a rudimentary level. Nearly or 
absolutelymute. Paraparetic or paraplegic with urinary and fecal 
incontinence. . (Atkinson et al,1995). 
  Prevalence of ADC is between 10-20% in Western countries(Grant 
et al,2005) and has only been seen in 1-2% of Indian HIV 
patients.(Satishchandra et al,2000;Wadia et al ,2001).Whether minor 
cognitive-motor disorder predisposes to HIV-associated dementia is also 
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of some debate. It appears that some patients may continue to have minor 
problems (Mandal et al, 2008), whereas another group progresses to frank 
dementia. (Masliah et al, 1996). 
 
ANTIRETROVIRAL THERAPY AND COGNITION 
  A neurologically active regimen was defined as one with 3 or more 
antiretroviral drugs known to penetrate the CNS in effective 
concentration. Individuals with advanced HIV infection receiving 3 or 
more neuroactive drugs showed a higher probability of reaching an 
undetectable cerebrospinal viral load. Seven antiretroviral drugs were 
defined as neuroactive drugs: nevirapine, efavirenz, stavudine, 
zidovudine, lamivudine, abacavir, and indinavir. Principles for selecting 
the first-line regimen (NACO, 2007) 
1. Choose 3TC (lamivudine) in all regimens 
2. Choose one NRTI to combine with 3TC (AZT or d4T) 
3. Choose one NNRTI. (NVP or EFV) 
In our ART center, Govt. Rajaji hospital, Madurai the combination 
of ZIDOVUDINE (300mg), LAMIVUDINE (150mg), NEVIRAPINE 
(200mg) was considered as  a preferred regimen and administered in  
most of the  patients.(NACO,2007). 
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Zidovudine (AZT) : 
Zidovudine, (also known as AZT or ZDV) was the first drug 
approved for the treatment of HIV, is an anti-HIV treatment in a class of 
drugs called nucleoside reverse transcriptase inhibitors (NRTIs).  The 
lowest effective dose of AZT has not been determined, and the currently 
recommended dose is 300-600 mg per day.  Side effects can be anaemia , 
leucopenia, lip, mouth and tongue sores, bone marrow damage confusion, 
loss of speech or appetite, muscle aches, fever abnormal bruising or 
bleeding.  
LAMIVUDINE(3TC) 
Lamivudine (also known as 3TC), is an anti-HIV treatment in the 
class of drugs called Nucleoside Reverse Transcriptase 
Inhibitors(NRTIs).The recommended dosage of Lamivudine is 150 mg 
twice a day. There is also a 300 mg once a day formulation. Lamivudine 
has few side-effects, mainly nausea, vomiting, headaches, and rare cases 
of hair loss. Although not as commonly  as with some other anti-HIV 
drugs, Lamivudine can cause peripheral neuropathy. A set of rare but 
serious side effects of nucleoside analog anti-HIV drugs is called lactic 
acidosis and severe hepatomegaly with steatosis (an enlarged fatty liver). 
Women, especially those who are oveweight, are particularly at risk 
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NEVIRAPINE 
Nevirapine falls in the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) class of antiretrovirals. Both nucleoside and non-
nucleoside RTIs inhibit the same target, the reverse transcriptase enzyme. 
The most common adverse effect of nevirapine is the development of 
mild or moderate rash (13%).Severe or life-threatening skin reactions 
have been observed in 1.5% of patients, including Stevens-Johnson 
syndrome, toxic epidermal necrolysis and hypersensitivity. Nevirapine 
may cause severe or life-threatening liver toxicity, usually emerging in 
the first six weeks of treatment. 
Since the introduction of Antiretroviral therapy, particularly after 
the concept of HAART (Highly active antiretroviral therapy) the debate 
regarding the effectiveness of HAART in the Neuropsychological 
impairment in HIV Patients continue in various part of the world. 
Sacktor et al (1998) studies the effect of HAART in the cognitive 
impairment due to HIV. They were studied 474 homosexuals and 
followed from 1995 to 1997 after giving HAART. The results showed 
that relative to antiretroviral naïve patients, HAART participants showed 
better performance over the course of one year in psychomotor speed and   
Trail making part B. 
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  Deutscha et al’s(2001) data support the view that   twice as many 
subjects (eight out of 22,36%) in the pre-HAART group developed new 
neuropsychological impairment than in the post-HAART group (four out 
of 24, 17 %). For all subjects, inclusion was restricted to those 
completing a detailed battery of neuropsychological tests at baseline and 
follow-up visits. These tests encompassed eight domains: 
abstraction/flexibility, attention/speed of information processing, 
learning, memory, verbal, perceptual-motor, motor, and sensory 
functioning. 
Starace et al (2002) showed that Neuropsychological deficit was 
found in 14.0% of subjects on HAART vs. 10.7% of subjects who were 
not taking HAART. In patients with AIDS, neuropsychological deficit 
was found in 37.1% of subjects on HAART Vs 33.3% of subjects who 
weren’t undergoing HAART regimen. 
Tozzi et al (2004) studied 70 subjects  on HAART and concluded 
that cognitive impairment in patients receiving HAART was associated 
with reduced HRQoL.(Health Related Quality of Life). Identifying 
cognitive impairment may provide motivation for additional treatment to 
help patients to compensate for deficits in functioning. 
Lucette et al (2004) done a study with 97 HIV positive 
patients.Among them 41 subjects on Neuroactive HAART and 56 
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subjects on HAART.The results showed that both groups did not differ 
from one another on neuropsychiatric performance,but both groups were 
impaired compared with controls and the neuroHAART group showed 
significantly better memory performance ,unrelated to plasma viral 
load,than the HAART group. 
Parson et al (2006)  investigated the relationship between HIV-
associated neurocognitive impairment and quality of life. HAART 
failures experienced slower psychomotor processing, and had increased 
self-reports of physical health complaints and substance abuse. 
Contrariwise, HAART successes experienced improved mental 
processing, demonstrating the impact of successful treatment on 
functioning. 
A Large scale longitudinal study done by McCutchan et al (2007) 
Of 433 advanced AIDS patients with documented immune reconstitution 
(CD4 lymphocyte counts < 50 before and > 100 cells/microl after 
HAART), 286 had brief assessments of cognition (Trailmaking A/B and 
Digit Symbol Tests) at least once, no confounding neurological 
conditions, and available neuropsychological norms with comprehensive 
demographic corrections revealed that improved performance on 
neuropsychological tests was documented over a 2-year period 3-5 years 
after initiating HAART. This improvement was marginally associated 
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with the continued or improving control of plasma HIV-RNA levels, but 
not with concurrent levels of immune recovery (CD4 lymphocyte counts). 
  Bartlett (2008) studied 284 participants with a baseline prevalence 
of neuropsychiatric impairment (NPI) of 27%. Sequential analysis 
showed NPI decreased significantly to 16% at week 48 and 14% at week 
96 after HAART. The author concluded that patients who responded to 
HAART for prolonged periods had stable or improving cognition, 
although continuing neurological recovery was incomplete on HAART.  
But the following studies raise the question about the effectiveness 
of HAART on cognitive impairment due to HIV. 
Dore et al (1999) collected data of All initial ADI (AIDS defining 
illness)cases in Australia over the period 1992-1997 . Three initial ADI 
groups were established: 1) ADC –AIDS DEMENTIA COMPLEX 
,2)other predominantly central nervous system (CNS) ADIs 
(toxoplasmosis and cryptococcosis); and  3)non-CNS ADIs. For each 
ADI grouping, the proportion of total ADls, and median CD4 cell count 
in the pre-HAART  era  were compared with the HAART era. They 
concluded that a proportional increase in ADC compared with other ADIs 
and a marked increase in the median CD4 cell count at ADC diagnosis 
have occurred since the introduction of HAART in Australia. These 
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changes suggest that HAART has a lesser impact on ADC than on other 
ADIs, with the poor CNS penetration of many antiretroviral agents a 
possible explanation.  
Wig et al(2004) from AIIMS done a follow up study and compared 
the patients on ART and without ART, but found no significant 
difference in cognitive performance. 
Tozzi et al (2005) study raise concerns regarding the clinical 
relevance of CNS involvement as potent antiretroviral therapies become 
less effective. 
Giancola et al (2006) studied 165 HIV-1 infected patients exposed 
to a stable highly active antiretroviral therapy (HAART) regimen and 
indicates that the use of stable HAART, including multiple drugs that 
have good CSF penetration, was not associated with neuropsychologic 
performance. To prevent independent replication of HIV in CSF with 
better control of a relevant reservoir of HIV is one of the crucial aims of 
therapeutic strategy. 
Nath and Sacktor (2006) opined that   highly actively antiretroviral 
therapy may need to be optimized in patients with HIV-associated 
cognitive impairment to achieve maximal central nervous system 
penetration; however, this therapeutic strategy may not be sufficient for 
halting the process. In some instances, the antiretroviral drugs themselves 
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may become the problem. New strategies for neuro  protection that also 
target host genes which control HIV replication are being developed. 
All of the above studies indicated   the various opinions about 
cognitive impairment in HIV patients , the predictors of the impairment 
and the impact of ART in the cognitive impairment. With this 
background the present study was conducted in our local setting to know 
about  the various features of HIV induced cognitive impairment. 
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MATERIALS AND 
METHODS 
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AIM OF THE STUDY: 
  To assess the prevalence and pattern of Neuropsychological 
impairment among HIV patients and to study longitudinally if ART (Anti 
retroviral therapy) has any impact on the   Neuropsychological decline. 
OBJECTIVES: 
 1. To assess the prevalence of cognitive impairment in HIV 
positive patients. 
 2. To know the pattern or type of cognitive impairment in the same 
patients. 
 3. To study the association between CD4 count and the level of 
impairment in cognition. 
 4. To know the effect of  Antiretroviral therapy in the cognitive 
decline due to HIV.     
     
 The Detailed review about the relationship between cognitive 
impairment in HIV, CD4 count, and Antiretroviral Therapy reveal certain 
areas of agreement and certain areas of disagreement. The present study 
is a longitudinal study based on a hypothesis –verification design with 
use of validated structured tools and definite statistical design. 
Methodology of the study was approved by the Institute Ethical 
Committee of Govt. Rajaji hospital. Study was conducted at ART- 
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Centre, Govt.Rajaji hospital, Madurai from the period of January 2008 to 
September 2008. Randomization was achieved by choosing consecutive 
patients who satisfied the following criteria. 
INCLUSION CRITERIA 
         1.  Seropositive patients diagnosed by ELISA Test. 
         2. Patients age should be between 18 years and 50 years. 
         3. He/She should be a literate. (Able to read and write) 
        4. Patient should be clinically   stable to attend the   interview. 
 5. Those who gave consent for initial study and for follow-up. 
EXCLUSION CRITERIA 
1. He /She should not suffer from present or past psychiatric illness  
including substance induced disorder.  
2. Patient should not have present or past neurological disorders. 
3. Patients with history of Head injury. 
4. He /She should not suffer from any sensory – motor impairment.  
5. Patients with severe medical illness or chronic drug intake that   
would interfere with the ability to perform the study.  
HYPOTHESIS: 
The following hypothesis were formulated    
    1. There will be a significant difference in the performance of    
       Neuropsychological functions between index and control groups. 
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    2. HIV causes cognitive impairment in various domains especially in  
 Attention, Mental speed, Motor speed, Memory, Intelligence. 
3. Performance became poor if the age increases. 
     4. Lower CD4 count associates with poor performance. 
5. Duration after HIV positivity is positively correlated with cognitive 
impairment. 
6. Antiretroviral therapy has a positive impact in the cognitive 
impairment. 
   
OPERATIONAL METHODS 
The  Medical officer in ICTC identified the cases for the study on 
the basis of HIV positivity by ELISA   then the author selected the 
subjects randomly based on the    inclusion criteria.   After ascertaining 
the fitness of the patient   for a detailed neuropsychiatric interview, the 
patient was  explained about the nature of the study. Confidentiality was 
assured. After obtaining the consent from the patient, the interview was 
held either in a single setting or in multiple setting as needed or on the 
request of the patient. This enabled the researcher to have co-operative 
and reliable interview with the patient. Since CD4 count 250 cells is the 
cut off range to start ART in HIV patients (followed in  our ART centre), 
30 consecutive patients with CD4 count less than 250 cells were assigned 
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as index cases and 30 patients with CD4 count more than 250 cells were 
taken as controls.   After screening them for socio- demographic and 
illness-related details, Psychiatric evaluation, Neurological assessment 
and neuro-psychological evaluation (sometimes on more than two 
sessions) were done with the following tools. Then Anti retroviral therapy 
with 3 drugs (Zidovudine,Lamivudine,Nevirapine) were instituted to the 
index  Cases since they had the CD4 count of less than 250 cells. Re-
evaluation was performed in both groups after 3 months. 
TOOLS USED: 
1. MINI-International Neuro-psychiatric Interview (Sheehan and 
Lecrubier ,1992) 
2. Standard  progressive matrices (Raven, 1989) 
3. Finger tapping test (Spreen and Stauss, 1998.) 
4. Digit symbol substitution Test (Wechsler,1981) 
5. Color Trails Test (D’ Elia et al,1996) 
6. Digit vigilance Test (Lezak, 1995) 
7. PGI Memory scale (Pershad, 1977) 
1.M.I.N.I(Mini Intenational Neuropsychiatric Interview) 
The M.I.N.I.(1990) is the most widely used psychiatric structured 
diagnostic interview instrument in the world.  The M.I.N.I. has been 
translated into 43 languages and is used by mental health professionals 
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and health organizations in more than 100 countries. The M.I.N.I. is a 
short, structured diagnostic interview that was developed in 1990 by 
psychiatrists and clinicians in the United States and Europe for DSM-IV 
and ICD-10 psychiatric disorders.  It includes modules for 23 disorders 
and features questions on rule-outs, disorder sub typing, and chronology. 
It also features a number of algorithms to handle hierarchical rule-outs in 
the event that the patient had more than one disorder at a time. With an 
administration time of approximately 15 minutes, the M.I.N.I. is the 
structured psychiatric interview of choice for psychiatric evaluation and 
outcome tracking in clinical psychopharmacology trials and 
epidemiological studies. The M.I.N.I. has been validated against the 
much longer Structure Clinical Interview for DSM diagnoses (SCID-P) in 
English and French and against the Composite International Diagnostic 
Interview for ICD-10 (CIDI) in English, French and Arabic.  It has also 
been validated against expert opinion in a large sample in four European 
countries (France, United Kingdom, Italy and Spain).In India during 2005 
a study on attempted suicide by Chandrasekeran et al used the MINI scale 
.Recently Venketsubramanian et al (2007) used this instrument to 
diagnose schizophrenia in their study on Relationship between Insulin 
growth factor and Schizophrenia. 
 
51
 
2. STANDARD PROGRESSIVE MATRICES 
Raven’s Standard Progressive Matrices(1936) (often referred to 
simply as Raven's Matrices) are multiple choice tests of 
abstract reasoning, also used for assessment for intelligence. Originally 
developed by Dr John C. Raven in 1936.  In each test item, a candidate is 
asked to identify the missing segment required to complete a larger 
pattern. Many items are presented in the form of a 3x3 or 2x2 matrix, 
giving the test its name. The booklet comprises five sets (A to E) of 12 
items each (e.g. A1 through to A12), with items within a set becoming 
increasingly difficult, requiring ever greater cognitive capacity to encode 
and analyze information. All items are presented in black ink on a white 
background.  The actual scores obtained by people living in most 
countries with a tradition of literacy - from China, Russia, and India 
through Europe to Kuwait - are very similar at any point in time. 
Adequate standardization, ease of use (without written or complex 
instructions), and minimal cost per person tested are the main reasons for 
its widespread international use in most countries of the world. 
3.FINGER TAPPING TEST 
The Finger Tapping Test is used to measure motor speed. There are 
several brain structures mediating motor speed. The prefrontal cortex 
mediates motor planning; the supplementary motor area mediates 
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initiation of motor acts, while the premotor cortex, basal ganglia and the 
cerebellum mediate fine motor control. Motor speed reflects the 
efficiency of this integration. The Finger Tapping Test measures the 
speed with which the index finger of each hand can tap. It consists of a 
tapping key mounted on a box. The Subjects taps the tapping key with the 
index finger of each hand. The subject is instructed to tap the key as fast 
as he/she without moving body or shoulder. The subjects is given a total 
of 5trials lasting 10 seconds each. The average number of taps over five 
trials forms the score of that hand. This test takes about 5minutes. 
4.DIGIT SYMBOL SUBSTITUTION TEST 
The Digit Symbol Substitution (Wechler, 1981) is a test of visuo 
motor coordination, motor persistence, sustained attention and response 
(mental) speed. Mental speed is a composite measure, which requires 
rapid processing of information also requires coordination of different 
areas of the brain. The  test consists of a sheet  in which numbers 1 to 9 
are randomly arranged in 4 rows of 25 squares each. The subject 
substitutes each number with a symbol using a number-symbol key given 
on the top of the page. The time taken to complete the test forms the 
score. Errors made are noted down. The test takes about 6-7minutes. 
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5.COLOR TRAILS TEST 
The color trails test (D’Elia et al,1996) was developed by the WHO 
as part of Multicenter study on HIV infection. The Test is an analogue of 
the Trail making test and is considered to be free from the influence of 
language. It has two parts .Part 1 requires sustained attention, perceptual 
tracking and simple sequencing while part 2 requires mental flexibility in 
addition to the above. The test is considered as a measure of focused 
attention because in both parts of the test, the subject has to ignore 
irrelevant numbers while scanning for the number, which is next in 
sequence. In each part a practice form precedes the test. 
6. DIGIT VIGILANCE TEST: 
 The Digit Vigilance Test (Lezak, 1995) consists of numbers 1 to 9 
randomly ordered and placed in rows on a page. There are 30 digits per 
row and they are closely packed. The same level of attention is required 
over a period of time. The subject has to focus on the target digits 2 and 8 
amongst other distracter digits. Time taken and number of errors were 
taken as scores. Inability to sustain and focus attention leads to both 
increased time to complete the test as well as errors.  
7. PGI MEMORY SCALE: (Persad 1997; Persad and Wig 1979) 
 It’s a Battery of Memory tests was constructed and standardized in 
1977(Persad 1997; Persad and Wig 1979) in India. Authors observe that 
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while constructing the test efforts were made to ensure that it is not 
unduly dependent on intelligence and is equally valid for both sexes and 
applicable and acceptable to illiterate and unsophisticated subjects who 
constitute the majority of subjects in Indian hospitals and clinics. The 
instruction and administration are simple.  The scale consists of ten 
subsets and intercorelation between them are moderate to negligible. 
Performance is not affected by scores in intelligence. The test-retest 
reliability ranged between 0.70 and 0.84 for psychotic groups.  0.48 and 
0.84 for normal group. 
 
STATISTICAL DESIGN: 
The following statistical methods were used in this study. 
        Central tendencies and the dispersion of the variables were studied 
using descriptive statistical methods such as mean, standard deviation. 
Comparison of the mean values between the groups was done using 
student’s t test and intra group comparison of the variables during the 
follow-up was studied by using paired t test. The significance of 
association between predictors and the neuropsychological testing was 
made out   by Pearson’s coefficient of correlation. The  significance of 
cognitive decline in the index group over three months in comparison to 
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that of the controls was studied by using Analysis of Covariance 
(ANCOVA).  
LIMITATIONS OF THE STUDY 
1. A larger sample size in both index and control groups could have 
made the results more generalisable. 
2. Consecutive follow up of the groups periodically for a longer period 
could have enabled a more detailed study of pattern of decline and the 
possible protective effect of ART.  
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RESULTS 
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TABLE-1. SOCIODEMOGRAPHIC  VARIABLES OF INDEX 
PATIENTS AND CONTROLS 
 
 
Index Group 
(N=30) 
Controls 
(N=30) 
 AGE   in  years 
             a)21 to 35 
             b) 35 to 50 
 
20 
10 
 
16 
14 
 INCOME 
   Above  Rs   2500 
   Below  Rs   2500               
 
11 
19 
 
8 
22 
  SEX                  
              Men 
              Women 
 
23 
 7 
 
22 
8 
  DOMICILE:              
              Rural                       
              Urban 
 
15 
15 
 
20 
10 
MARITAL   STATUS 
            Married 
            Single 
 
25 
 5 
 
26 
 4 
OCCUPATION 
            Salaried 
            Self-Employed 
 
21 
9 
 
20 
10 
EDUCATION: 
         7 to 10TH STD 
         Above 10TH STD 
 
22 
8 
 
23 
7 
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Table I shows the Demographic variables of both subjects and 
control groups. It shows that about 66% (20 out of 30) of the index 
patients are less than 35 years. In control groups about 53% peoples are 
less than 35 years. Both groups represent the most affected age group. 
Both  group consists of about 75% of male members and indicating 
the high prevalence and awareness of male population. In the index 
groups rural and urban people represent almost equal (50%) percentage 
where as in the control group rural people slightly predominate. 
About 80% in both groups are married and in both groups about   
30% in both groups are self/un employed others are working as salaried 
individual. 
Lowest education in both groups are 7th standard, about 26%   in 
both groups are studied above 10th standard. 
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TABLE-2.  Comparison of disease related variables of index and 
control groups 
 
 
CASES (N-30) 
MEAN  (S.D) 
CONTROLS(N-30) 
MEAN (S.D) 
 
‘t’ 
 
CD-4 COUNT 
 
 
190.89(79.4) 
 
361.70(68.3) 
 
9.45** 
DURATION in 
months 
 
16.89(12.6) 10.93(6.8) 2.71** 
BLOOD UREA 
 
24.33(7.7) 25.13(5.2) 0.49 
BLOOD SUGAR  
 
96.03(16.3) 98.53(14.0) 0.56 
 
Df = 58  ** p < .01 
 
Table -2 shows the comparison of disease related variables 
indicated  that CD4 count was lower and duration of illness longer for the 
index group and the difference was statistically significant.  Blood urea 
and blood sugar did not differ significantly. 
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TABLE-3 Comparison of neuropsychological performance of index  
and control groups 
 
 
CASES (N-30) 
 MEAN(S.D) 
CONTROLS (N-30) 
MEAN  (S.D) 
 
‘t’ 
 
Raven’s Matrices 
 
18.86(4.8) 
 
20.13 (4.7) 
 
1.65 
 Finger Tapping      
                Right 
                Left         
 
29.70(3.3) 
29.00(3.5) 
 
28.80(2.7) 
27.60( 2.3) 
 
1.37 
1.91 
Digit Symbol test 7.76(2.9) 5.43(1.8) 1.44 
Color Trail 
                       1    
                       2      
 
4.10(1.5) 
7.20(2.1) 
 
3.16(0.6) 
5.96(1.2) 
 
3.24** 
2.90** 
Digit Vigilance   
            Time           
             Error 
 
4.33(1.1) 
1.16(1.5) 
 
3.83(1.3) 
0.50(0.7) 
 
1.66 
2.36* 
PGI Memory 
Scale 
 
75.43( 9.6) 
 
79.00( 7.2) 
 
1.72 
Df = 58.                                                               * p < .05; ** p < .01. 
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  Table – 3  : Comparison of neuropsychological performance of 
index and control groups showed that in color trail test 1 and 2 and in 
Digit Vigilance-Error score statistically significant differences were 
observed. Even though Index patients scored lower in Raven’s matrices 
and PGI memory scale scores and had longer duration in Finger Tapping 
1 and 2 and Digit Vigilance-Time than the controls, the differences were 
not statistically  significant . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62
 
TABLE 4 Correlation between disease variables and 
neuropsychological performances among the index patients 
 Values refer to Pearson’s γ. 
 * p < .05; ** p < .01. 
Values given with * are statistically significant. 
 
 
 AGE DURATION CD-4 
Raven’s Matrices 0.04 0.26 -0.05 
Finger  Tapping 
  Right 
 Left 
 
 0.11 
 0.12 
 
-0.13 
-0.14 
 
0.13 
0.18 
Digit symbol   0.27 -0.06 -0.21 
Color Trail test 
       One 
        Two 
 
 0.25 
 0.31 
 
0.04 
0.03 
 
-0.28 
-0.24 
Digit Vigilance 
 Time 
 Error  
 
  0.42** 
  -0.08 
 
-0.31 
0.02 
 
-0.19 
-0.14 
PGI Memory Scale -0.21 0.07 0.31 
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Correlation between neuropsychological performance and disease-
related variables showed that Digit Vigilance-Time was significantly 
correlated with age and other associations were not statistically 
significant. 
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TABLE-5 -Comparison of the cognitive scores in index patients  both 
during initial evaluation and  three months after ART 
 
 
CASES (N-30) 
MEAN(S.D) 
FOLLOWUP (N-30) 
MEAN  (S.D) 
Paired 
‘t’ 
 
Raven’s Matrices 
 
18.86(4.8) 
 
19.07(4.6) 
 
2.26* 
 
 
Finger Tapping      
                Right 
                Left        
 
29.70(3.3) 
29.00(3.5) 
 
29.53(3.0) 
28.83(3.26) 
 
1.40 
1.30 
Digit Symbol test 7.76(2.9) 7.40(2.0) 2.01 
Color Trail 
                          1   
                          2   
 
4.10(1.5) 
7.20(2.1) 
 
  4.03 (1.4) 
6.87(2.0) 
 
1.14 
 2.27* 
 Digit Vigilance   
                   Time  
                   Error 
 
4.33(1.1) 
1.16(1.5) 
 
4.3(1.7) 
 0.77(1.1) 
 
0.37 
1.98 
PGI scale 75.43( 9.6) 75.50( 9.1) 0.23 
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Table 5 showed the comparison of the cognitive scores in index 
patients  both during initial evaluation and  three months after ART, 
indicated that there was a stasticaly significant differnces were noticed in  
Raven’s test and color trail test two.There was notable differences in 
Digit vigilance error and digit vigilance scores,but they  are not 
statisticaly significant. 
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TABLE-6  Comparison of neuropsychological performance 
scores of control patients  both during initial and  follow up 
visits (after 3 months) 
 CONTROLS (N-30) 
MEAN (SD) 
FOLLOWUP (N-
30) 
MEAN(SD) 
PAIRED
 ‘ t’ 
Raven’s Matrices 20.13 (4.7) 20.37(4.3) 0.74  
Finger tapping        
               Right 
               Left          
 
28.80(2.7) 
27.60( 2.3) 
 
28.70(2.7) 
27.67(2.3) 
 
 1.13 
 1.00 
Digit Symbol test 5.43(1.8) 5.43(1.9)  0.00 
Color Trail  
1                            
2                             
 
3.16(0.6) 
5.96(1.2) 
 
3.13(0.7) 
6.00(1.3) 
 
1.00 
0.57 
 Digit vigilance   
               Time 
               Error 
 
3.83(1.3) 
0.50(0.7) 
 
3.80(1.3) 
0.57(0.77) 
 
1.00 
1.14 
PGI scale 79.00( 7.2) 79.10(7.3) 0.83 
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Table-6 showed the Comparison of neuropsychological 
performance  scores of control patients  both during initial and  follow up 
visits (after 3 months).It indicated that there was some negligible 
differences  in the scores of  Raven’s matrices and PGI memory scale but 
they were not statistically significant. Almost no changes were noted in 
the scores of digit vigilance and digit symbol substitution test. 
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TABLE-7  Comparison of neuropsychological functions of index 
group and the control group over three months’ followup. 
 
 
Cases 
Mean (S.D) 
Followup  
Mean (S.D) 
Controls 
Mean (SD) 
Followup 
Mean(SD) 
 
  F 
Raven’s Matrices 18.86(4.8) 19.07(4.6) 20.13 (4.7) 20.37(4.3) 0.27 
Finger Tapping        
               Right 
                Left          
 
29.70(3.3) 
29.00(3.5) 
 
29.53(3.0) 
28.83(3.26) 
 
28.80(2.7) 
27.60( 2.3) 
 
28.70(2.7) 
27.67(2.3) 
 
0.01 
0.53 
Digit Symbol test 7.76(2.9) 7.40(2.0) 5.43(1.8) 5.43(1.9) 0.05 
Color Trail 
                        1   
                        2      
 
4.10(1.5) 
7.20(2.1) 
 
  4.03 (1.4) 
6.87(2.0) 
 
3.16(0.6) 
5.96(1.2) 
 
3.13(0.7) 
6.00(1.3) 
 
0 
2.32 
 Digit Vigilance   
                 Time  
                  Error 
 
4.33(1.1) 
1.16(1.5) 
 
4.3(1.7) 
 0.77(1.1) 
 
3.83(1.3) 
0.50(0.7) 
 
3.80(1.3) 
0.57(0.77) 
 
0.01 
1.33 
PGI scale 75.43( 9.6) 75.50( 9.1) 79.00( 7.2) 79.10(7.3) 0.27 
Df-58      *<0.5,p*<0.01 
TABLE-7 showed the Comparison of neuropsychological 
functions of index group and the control group over three months’ 
followup, none of the variables were significant. 
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DISCUSSION 
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Neurocognitive changes have been documented along various 
dimensions, with varying severity in different stages of HIV-AIDS 
disease. Atkinson and Grant (1994) reported an annual rate of HIV 
dementia in 7 to 14% of the patients and that psychopathology due to 
milder form of cognitive impairment occurred in half of the patients with 
frank AIDS. Though during early stages, the impairments were mild, they 
exerted a summated decline in the individual’s behavioral adaptation, 
vocational efficiency and quality of life (Edwin et al, 1999). Different 
cognitive functions showed a different lag in onset and have a differing 
course of decline (Gupta et al, 2007; Skolasky et al, 2007). Some of these 
changes were amenable to earlier management with anti retroviral 
therapy (Cysique et al, 2004). 
Previous studies have documented the nature and extent of 
neuropsychological changes in different phases of the disease but there 
were differences in considering ART as preventive of further 
deterioration of the impairments. Hence, the study was based on 
Hypothesis verification design. The index group and control group were 
identified with definite homogenization and comparability. Measures of 
impairment were frequently-used neuropsychological tools, previously 
used in native population and with an acceptable validity. 
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The present study was conducted on the most immuno-suppressed 
group (CD4 count < 250 cells) and the socio-demographic profile of 
predominantly middle aged, married men of average education from both 
rural and urban domicile. Since most of the people attending ICTC had 
similar socio economic profile, these patients may be considered as 
representative of the those attending the ICTC. Comparability between 
the two groups was maintained. 
Comparison of the physical parameters showed that CD4 count and 
duration of the illness were significantly different. The difference in CD4 
count was expected as it formed the criteria for the difference between the 
index patients and controls. Longer duration of the illness in these 
patients indicated that increasing immuno-suppression was the resultant 
of length of the illness. Biochemical parameters like blood urea, sugar in 
both groups did not vary significantly. 
Comparison of neuropsychological performance of the patients 
with the controls showed that patients were significantly poor in Colour 
Trail test 1 and 2 and made more errors in Digit Vigilance test. Colour 
trails test is a measure of sustained attention. Increasing error-proneness 
in Digit Vigilance further indicated their inability to sustain attention. 
Disturbances in attention have been identified as a hallmark of early 
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disturbance and rapid decline in HIV related neuro-cogntive disturbances 
(Edwin et al, 1999; Cysique et al, 2002; Cysique et al, 2004). Correlations 
between illness-variables and decline in attention have been recognized 
as resulting in secondary memory disturbances (Carey et al, 2006 ) but in 
our study no significant impairment in memory was noted. Though 
during early stages, the impairments were mild, they exerted a summated 
decline in the individual’s behavioral adaptation, vocational efficiency 
and quality of life (Tozzi et al, 2004).  
The pattern of neuropsychlogical deficits found in this study is 
similar to what has been found in USA, Uganda and Australia where HIV 
Clades A,B,D are highly prevalent.(Janssen et al,1992; Portegies et 
al,1993; Kevin Robertson,2007). In India, clade C is the predominant one 
and underlying neuropathology is same in various clades. 
Correlations between illness-variables and neuropsychological 
performance did not show any statistically significant association, except 
between duration in Digit Vigilance Test and age of the individual. 
Sacktor et al (2007) observed similar differences in aged HIV patients 
and concluded that age was associated with lower performance interests 
of memory, executive functions and motor performance. They attributed 
such differences to changes due to advanced age itself or due to age-
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associated co-morbidities. The CD4 cell count of the HIV-seropositive 
subjects had no significant correlation with the cognitive test scores. The 
results were similar to the findings of Villa et al (1996). Wig et al (2004) 
and Salowu (2008) found that there was a negative correlation between 
CD4 count and attention. According to Odiase et al (2007) there was 
impaired ability for sustained attention irrespective of the CD4 level 
relative to controls. 
Comparison of cognitive scores in the index patients before and 
after 3 months of ART found a significant difference in Standard 
progressive matrices and in color trail 2 indicated that there was a definite 
change in attention as well as in mental flexibility. Similar comparison in 
the control didn’t show difference in any of the tests. Thus, significant 
improvements in the index group were unlikely to be a derivative of 
practice effects. Early changes in response to ART were also observed in 
other studies especially in attentional functions (Cysique et al, 2004). 
Analysis of Covariance between the groups considering their 
performances in the initial assessment and at three months’ follow-up 
showed that the improvements in index group were not significantly more 
than the improvements of the control group in any of the dimensions of 
neuropsychological functions. Incremental changes observed in the index 
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group during follow-up were not sufficiently incremental to attain 
statistical significance. The insufficiency could be a resultant of the short 
duration of follow-up and might become prominent in continued follow-
up evaluations (Sacktor et al, 2005). The possibility of improvement is 
explainable as resulting from any of neuropsychological reconstructive 
processes and if provable in long term follow-up studies could point to an 
effective way of preventing neuro-cognitive decline. 
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CONCLUSION  
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This longitudinal study has the objective to analyse the pattern of 
neuropsychological impairment in HIV positive patients and the impact 
of Antiretroviral Therapy on Cognitive impairment.The findings in the 
study bring to light certain observations which, inspite of the limitations 
in the study,may be generalizable. It has been inferred that 
1.There was significantly more  impairment in  neuroopsychological 
functons in the index patients  in comparision to controls.  
2. Signifcant  impairment in  both sustained and focused attention was 
noted from our study. 
3.No significant difference was noted in Mental speed,Motor speed and 
Memory. 
4.Age and duration after postivity were possitvely correlated with 
neuropsychologcal performance. 
5.CD4 count has no positive correlation with the cognitive scores. 
6.Antiretroviral Therapy improves the neuropsychologcal performance 
especialy in sustained attention as well as in mental flexibility. 
Neuropsychological deficits particularly in attention were likely to 
influence the patients activities of daily living and ability to maintain 
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employment. Early recognition and treatment of cognitive dysfunction by 
involving psychiatrist as a team member in the ART or by mandatory 
opinion of the psychiatrist for all HIV positive patients may lead to a 
better outcome. Further studies to characterize HIV associated cognitive 
impairments and their impact in daily living and employment are 
necessary. 
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APPENDIX-I 
PROFORMA 
S.No   :      Date: 
Name   : 
Address  : 
 
Age   : 
Sex   : Male/Female In Patient / Outpatient 
Education  : 
Occupations  : 
Income  : 
Marital Status : 
Handedness  : 
 
Regarding HIV 
CD4 Count    : 
WHO Staging I / II / III / IV : 
 
Clinical Observations 
Sensory Function of 
Vision / Hearing / Touch  : 
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Motor Functions   : 
H/O Com Medical Illness : 
H/O Substance Dependence  : 
H/O Head Injury   : 
H/O Mental Illness  : 
Family History   : Mental Illness / Neurological Illness____ 
Lab Investigations 
Blood Urea  : 
Blood Sugar  : 
SGOT  : 
SGPT   : 
Case History 
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APPENDIX-II 
 
MINI NEUROPSYCHIATRIC INTERVIEW 
GENERAL INSTRUCTIONS:  
The M.I.N.I. was designed as a brief structured interview for the 
major Axis I psychiatric disorders in DSM-IV and ICD-10.  Validation 
and reliability studies have been done comparing the M.I.N.I. to the 
SCID-P for DSM-III-R and the CIDI (a structured interview developed 
by the World Health Organization).  The results of these studies show 
that the M.I.N.I. has similar reliability and validity properties, but can be 
administered in a much shorter period of time (mean 18.7 ± 11.6 minutes, 
median 15 minutes) than the above referenced instruments.  It can be 
used by clinicians, after a brief training session.  Lay interviewers require 
more extensive training. 
GENERAL FORMAT: 
 The M.I.N.I. is divided into modules identified by letters, each 
corresponding to a diagnostic category. 
 •At the beginning of each diagnostic module (except for psychotic 
disorders module), screening question(s) corresponding to the main 
criteria of the disorder are presented in a gray box. 
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 •At the end of each module, diagnostic box(es) permit the clinician 
to indicate whether diagnostic criteria are met. 
RATING INSTRUCTIONS: 
All questions must be rated. The rating is done at the right of each 
question by circling either Yes or No.  Clinical judgment by the rater 
should be used in coding the responses.  Interviewers need to be sensitive 
to the diversity of cultural beliefs in their administration of questions and 
rating of responses. The rater should ask for examples when necessary, to 
ensure accurate coding.  The patient should be encouraged to ask for 
clarification on any question that is not absolutely clear. 
The clinician should be sure that each dimension of the question is 
taken into account by the patient (for example, time frame, frequency, 
severity, and/or alternatives).Symptoms better accounted for by an 
organic cause or by the use of alcohol or drugs should not be coded 
positive in the M.I.N.I.   
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APPENDIX-III 
STANDARD PROGRESSIVE MATRICES 
Raven’s Standard Progressive Matrices (often referred to simply 
as Raven's Matrices) are multiple choice tests of abstract reasoning, also 
used for assessment for intelligence.  In each test item, a candidate is 
asked to identify the missing segment required to complete a larger 
pattern. Many items are presented in the form of a 3x3 or 2x2 matrix, 
giving the test its name. The booklet comprises five sets (A to E) of 12 
items each (e.g. A1 through to A12), with items within a set becoming 
increasingly difficult, requiring ever greater cognitive capacity to encode 
and analyze information. All items are presented in black ink on a white 
background. 
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APPENDIX-IV 
  DIGIT SYMBOL SUBSTITUTION TEST 
1  2  3  4  5  6  7  8  9 
-  ⊥  ⊃  L  ∪  O  ^  x  = 
 
2 1 3 7 2 4 8 1 5 4 2 1 3 2 1 4 2 3 5 2 3 1 4 6 3
 
 
                        
 
1 5 4 2 7 6 3 5 7 2 8 5 4 6 3 7 2 8 1 9 5 8 4 7 3
 
 
                        
 
6 2 5 1 9 2 8 3 7 4 6 5 9 4 8 3 7 2 6 1 5 4 6 3 7
 
 
                        
 
9 2 8 1 7 9 4 6 8 5 8 7 1 8 5 2 9 4 8 6 3 7 9 8 6
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APPENDIX-V 
     
COLOR TRAIL TEST -ONE 
 
 
 
 
 
 
25 
21 
23 
7 
4 
15 12 
6 
20 
24 
8 
16 
1 
11 
9 
10 
14 
18 
19 
22 
2 
5 
3 
17 
13 
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APPENDIX-VI 
   COLOR TRAIL TEST-TWO 
 
 
 
13 
6 9 
4 
11 
8 
21 
23 
10 
2 
24 20 
12 
9 
25 
6 
15 
17 18 
2 
7 
3 
14 
19 
22 
5 
16 
7
13 
3 
24 
1 
12 
5 
8 
21 
14 
2 
4 
17 
19 
22 10 
18 
16 
23 
20 
15 
11 
25
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APPENDIX-VI 
DIGIT VIGILANCE TEST 
“2” and “8” 
6 2 6 7 2 3 1 3 8 5 5 5 8 1 7 9 1 7 2 7 4 5 7 6 1 3 9 6
 
2 
 
7 
 
1 
 
5 
 
2 
 
7 
 
9 
 
1
 
9
 
4
 
6
 
9
 
5
 
7
 
1
 
8
 
9
 
5
 
6 
 
5 
 
4 
 
2 
 
1
 
1
 
6
 
9
 
7
 
5
9 4 6 9 5 7 1 8 9 5 6 5 4 2 7 1 5 2 7 9 1 7 1 1 1 4 2 8
 
5 
 
1 
 
8 
 
3 
 
4 
 
2 
 
6 
 
9
 
9
 
9
 
6
 
7
 
8
 
6
 
7
 
1
 
7
 
1
 
3 
 
4 
 
3 
 
9 
 
8
 
4
 
2
 
7
 
1
 
5
1 9 7 9 7 1 6 7 8 6 5 5 7 2 9 6 5 9 5 4 7 3 2 4 5 6 1 4
                           
4 6 8 4 1 4 1 7 2 4 7 1 7 6 7 5 4 9 8 7 5 6 2 1 6 9 3 1
                           
7 8 6 7 1 7 1 3 4 3 9 8 6 5 1 8 3 4 2 6 9 9 6 1 6 4 3 9
                           
4 9 3 8 7 2 5 4 4 8 7 6 4 1 4 7 2 6 8 7 5 6 3 2 6 4 4 6
                           
4 8 6 4 7 5 4 4 7 9 7 3 6 8 6 5 4 7 4 3 4 9 2 5 3 5 4 7
                           
4 9 3 3 8 1 8 4 2 6 5 6 6 1 7 2 4 2 9 7 9 7 6 1 5 1 4 1
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APPENDIX-VII 
PGI MEMORY SCALE 
 
PGI Memory Scale:   
I. Remote Memory   
1. Age   
2. Birth Place   
3. a) When were you married?   
 b) When did you start working?   
 c) When did you stop your education?   
4. What’s your last child age / brother’s age?   
5. When did you first came to GRH?   
6. When did you visit the ward for the first time? (ART)   
     /6  
    
II. Recent Memory   
1. Supper last night?   
2. Breakfast this morning?   
3. Name of this month?   
4. Day is to-day?   
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5. Whom did you meet yesterday?   
   /5  
   
III. Mental Balances   
1. A, B, ……… Z (or) A,B,C,..........   
2. 20-0 in reverse   
3. 40-3 in reverse   
    /3  
   
IV. Attention and Concentration   
1. DF   
(a) 5-7-3  (b) 4-7   
     5-3-87        6-5-8   
     4-6-4-95        29763   
2. DB   
 8 -5   2-8   
 4 3 7   8-5-1   
 8 5 6 3  3 7 5 9   
 4 7 2 9 1  6 1 5 8 3   
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V. Delayed Recall (Repeat after one minute)    
(1)  Umbrella  (2) Fish   
Flower        Lamp   
Clock        Rupee   
Picture         Taj   
Pencil         Doll   
     /10  
   
VI. Immediate Recall   
1. Rama getup from the chair, opened the door and 
wentout 
 
 
    /3  
2. The patient was laid on the couch, Examined, 
Prescription was written and asked to come next day 
 
 
    /4  
3. No water in Mohan’s House, took the bucket went to the 
top he street, filled it with water at returned 
 
 
    /5  
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VII. Verbal Retention for Similar Pairs Trial-1 Trial-2 Trial-3   
1. UWm   ×      
2. CÉlé   LNlé      
3. Bi  ùTi      
4. TLp   CWî      
5. Lñlé   ùYsû[      
Total        /5      /5      /5 
      
/15 
 
      
VIII. For Dissimilar Pairs Trial-1 Trial-2 Trial-3   
1. úUû_  Lñlé        
2. UWm  EVWm       
3. Å[dá  L¼]m       
4. áZkûR  LNlé        
5. L]î  BZm        
Total        /5      /5      /5   /15  
IX. Visual Retention (Cards 1 to 3 = 1 scores each  (6) 
      4 = 3 scores  (3) 
      5 = 4 scores  (4) 
      Total =  /13 
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1. Card -1   
2. Card -2   
3. Card -3   
4. Card -4   
5. Card -5   
X. Recognition (Total 10) 
 No. of Objects Correctly Recognized (-) - 
 No. of Objects Wrongly Recognized   - 
    Total Score   - /10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
